Development of an Adeno-Associated Virus-Vectored SARS-CoV-2 Vaccine and Its Immunogenicity in Mice.
AAV9
SARS-CoV-2
immune
long term protection
vaccine
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2022
2022
Historique:
received:
26
10
2021
accepted:
08
02
2022
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
1
4
2022
Statut:
epublish
Résumé
Owing to the outbreak of the novel coronavirus (SARS-CoV-2) worldwide at the end of 2019, the development of a SARS-CoV-2 vaccine became an urgent need. In this study, we developed a type 9 adeno-associated virus vectored vaccine candidate expressing a dimeric receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S protein) and evaluated its immunogenicity in a murine model. The vaccine candidate, named AAV9-RBD virus, was constructed by inserting a signal peptide to the N-terminus of two copies of RBD, spaced by a linker, into the genome of a type 9 adeno-associated virus.
Identifiants
pubmed: 35310850
doi: 10.3389/fcimb.2022.802147
pmc: PMC8927296
doi:
Substances chimiques
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
802147Informations de copyright
Copyright © 2022 Qin, Li, Li, Pei, Liu, Ding, Liu, Bi, Shi, Guo, Fang, Huang, Yu, Zhu, An, Valencia, Li, Dong and Zhou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2016 Aug 13;388(10045):661-72
pubmed: 27375040
Lancet Infect Dis. 2021 Aug;21(8):1107-1119
pubmed: 33773111
Nat Rev Drug Discov. 2019 May;18(5):358-378
pubmed: 30710128
PLoS Pathog. 2010 Jul 08;6(7):e1000985
pubmed: 20628575
Mol Ther. 2004 Aug;10(2):302-17
pubmed: 15294177
Nat Rev Genet. 2014 Jul;15(7):445-51
pubmed: 24840552
Lancet. 2015 Dec 12;386(10011):2395-403
pubmed: 26431823
PLoS Pathog. 2021 Jul 15;17(7):e1009544
pubmed: 34265018
Mol Ther. 2020 Sep 2;28(9):2073-2082
pubmed: 32559433
Mol Ther. 2004 Dec;10(6):981-9
pubmed: 15564130
Emerg Microbes Infect. 2020 Dec;9(1):680-686
pubmed: 32207377
Vaccines (Basel). 2021 Jan 21;9(2):
pubmed: 33494530
N Engl J Med. 2017 Dec 7;377(23):2215-2227
pubmed: 29211678
BioDrugs. 2017 Aug;31(4):317-334
pubmed: 28669112
N Engl J Med. 2020 Jan 2;382(1):29-40
pubmed: 31893514
Front Mol Biosci. 2021 Apr 22;8:671633
pubmed: 33968996
Nat Protoc. 2020 Nov;15(11):3699-3715
pubmed: 32978602
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Exp Eye Res. 2003 Mar;76(3):373-83
pubmed: 12573666
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Expert Opin Biol Ther. 2011 Mar;11(3):315-27
pubmed: 21204741
Hum Gene Ther Clin Dev. 2014 Jun;25(2):72-84
pubmed: 24720466
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Clin Microbiol Rev. 2008 Oct;21(4):583-93
pubmed: 18854481
Curr Gene Ther. 2013 Dec;13(6):434-52
pubmed: 24195602
J Virol. 2008 Aug;82(16):7875-85
pubmed: 18524821
BMC Bioinformatics. 2008 Dec 12;9 Suppl 12:S15
pubmed: 19091014
Mol Ther. 2008 Jul;16(7):1189-99
pubmed: 18500252
Science. 2020 Jun 12;368(6496):1274-1278
pubmed: 32404477
Adv Drug Deliv Rev. 2006 May 20;58(2):243-58
pubmed: 16563557
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Cell Res. 2020 Oct;30(10):932-935
pubmed: 32759966
Mol Ther. 2017 Jun 7;25(6):1387-1394
pubmed: 28408179
Cell Host Microbe. 2021 Sep 8;29(9):1437-1453.e8
pubmed: 34428428
Science. 2007 Jul 27;317(5837):477
pubmed: 17656716
N Engl J Med. 2017 Dec 28;377(26):2519-2530
pubmed: 29224506
Mol Ther. 2008 Jun;16(6):1073-80
pubmed: 18414476
EMBO Mol Med. 2020 May 8;12(5):e10938
pubmed: 32163240